Hormonal Pattern and Testicular Histology in Patients with Prostatic Cancer after Long-Term Treatment with a Gonadotropin-Releasing Hormone Agonist Analogue

1988 ◽  
Vol 15 (1-2) ◽  
pp. 125-127 ◽  
Author(s):  
Claudio Giberti ◽  
Tommaso Barreca ◽  
Giuseppe Martorana ◽  
Mauro Truini ◽  
Roberto Francheschini ◽  
...  
Keyword(s):  
Prostatic Cancer ◽  
Term Treatment ◽  
Gonadotropin Releasing Hormone ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist ◽  
Long Term Treatment ◽  
Testicular Histology

Effects of long-term treatment with the gonadotropin-releasing hormone analog nafarelin in patients with non-functioning pituitary adenomas

1994 ◽  
Vol 130 (4) ◽  
pp. 339-345 ◽  
Author(s):  
Paolo Colombo ◽  
Bruno Ambrosi ◽  
Katia Saccomanno ◽  
Monique Bassetti ◽  
Donatella Cortelazzi ◽  
...  
Keyword(s):  
Pituitary Adenomas ◽  
Term Treatment ◽  
Gonadotropin Releasing Hormone ◽  
Gnrh Analog ◽  
Hormonal Responses ◽  
Releasing Hormone ◽  
Hormone Analog ◽  
Long Term Treatment ◽  
Non Functioning Pituitary Adenomas

Colombo P, Ambrosi B, Saccomanno K, Bassetti M, Cortelazzi D, Faglia G. Effects of long-term treatment with the gonadotropin-releasing hormone analog nafarelin in patients with non-functioning pituitary adenomas. Eur J Endocrinol 1994;130:339–45. ISSN 0804–4643 The supposed origin of non-functioning pituitary adenomas (NFPA) from gonadotrophs prompted us to investigate the effects of the gonadotropin-releasing hormone (GnRH) analog nafarelin on hormonal and tumoral parameters in eight patients with NFPA, previously unsuccessfully operated and all hypogonadal. Nafarelin was administered intranasally for 1 year to all patients. Four patients received a dose of 1200 μg/day; the remaining four received 800 μg/day for 3 months, which was subsequently increased to 1200 μg/day. Basal gonadotropin and α-subunit (αSU) levels were low–normal. In four patients (nos. 1,2,3,5) nafarelin significantly lowered luteinizing hormone (LH) levels, and also folliclestimulating hormone (FSH) in three of them (nos. 1,2,3). Persistent FSH stimulation occurred in three patients (nos. 6,7,8), with a transient slight LH increase only in patient no. 8. In one patient (no. 7), αSU levels were persistently stimulated. Hormonal responses to an acute GnRH test during nafarelin administration were generally blunted when compared to the pretreatment responses. Immunofluorescence results, obtained before treatment in five adenomas (nos. 2,3,4,6,7), had been as follows: positive for FSH-β in all; negative for LH-β in all, except a few positive cells in case no. 4; positive for αSU in three (nos. 2,3,7). No changes of visual field and tumor size occurred in any patient during treatment. However, one patient who showed a persistent increase in FSH levels exhibited left palpebral ptosis after 12 months of therapy and underwent a second transsphenoidal surgery. In conclusion: NFPA behave heterogeneously in terms of hormonal responses to GnRH analog therapy; long-term nafarelin treatment was unsuccessful in reducing the size of NFPA; and stimulation rather than inhibition of gonadotropin levels may suggest discontinuance of GnRH analog therapy in NFPA. Paolo Colombo, Istituto di Scienze Endocrine, Ospedale Maggiore IRCCS-Pad, Granelli, via F. Sforza 35, 20122 Milano, Italy

scholarly journals Comparative response of rams and bulls to long-term treatment with gonadotropin-releasing hormone analogs

2007 ◽  
Vol 98 (3-4) ◽  
pp. 204-224 ◽  
Author(s):  
H. Jiménez-Severiano ◽  
M.J. D’Occhio ◽  
D.D. Lunstra ◽  
M.L. Mussard ◽  
T.L. Davis ◽  
...  
Keyword(s):  
Term Treatment ◽  
Gonadotropin Releasing Hormone ◽  
Releasing Hormone ◽  
Long Term Treatment ◽  
Comparative Response ◽  
Hormone Analogs

scholarly journals A retrospective, observational, single center study of gonadotropin-releasing hormone agonist protocols at the Reproductive Center of Farah Hospital in Jordan

2019 ◽  
Vol 7 (8) ◽  
pp. 3103
Author(s):  
Zaid Kilani ◽  
Mohammad Shaban
Keyword(s):  
Term Treatment ◽  
Gonadotropin Releasing Hormone ◽  
Clinical Pregnancy ◽  
Short Term ◽  
Short Term Treatment ◽  
Releasing Hormone ◽  
Long Term Treatment ◽  
Group A

Background: Data on infertility and in vitro fertilization (IVF) are incomplete and uncertain in Jordan and worldwide because of difficulties in evaluating infertility in the general population. This study aimed at comparing the effectiveness of the gonadotropin-releasing hormone agonists (GnRH-a) long and short protocols as part of IVF or intracytoplasmic sperm injection.Methods: This observational, retrospective, comparative, longitudinal study was conducted in a reproductive center in Jordan. It reviewed data charts from women who took GnRH-a for IVF, from 2010 to 2013. These were categorized in Group A (long-term GnRH-a: single 3.75 mg-monthly injection) or Group B (short-term GnRH-a: multiple daily 0.1 mg injections). The primary endpoint was the rate of ongoing clinical pregnancy (number of pregnancies/number of women) and live birth rate in fresh cycle/protocols.Results: Out of 1,946 eligible women, 471 underwent the long-term treatment of GnRH-a administration and 1,523 the short-term treatment. The women’s mean age was 29.61±3.80 years old. Out of the 471 women in Group A, 216 (45.9%) women had ongoing clinical pregnancy, of whom 69 (31.9%) had live births. In the short-protocol group, 485 (31.8%) women had ongoing clinical pregnancy, of whom 133 (27.4%) had live births.Conclusions: GnRH-a long protocol is more effective than the short protocol regardless of the agonist formulation used in subfertile women/men who underwent IVF/ intracytoplasmic sperm injection.

Sign in / Sign up

Export Citation Format

Share Document